ABCL Q4 2021 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$139M-33.0% YoY

Gross Profit

$117M84.3% margin

Operating Income

$82M58.5% margin

Net Income

$60M43.0% margin

EPS (Diluted)

$0.19

QoQ Revenue Growth

+2429.6%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$26M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$293M

Stockholders' Equity

$1.0B

Cash & Equivalents

$476M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$139M	$208M	-33.0%
Gross Profit	$117M	$0	—
Operating Income	$82M	$161M	-49.3%
Net Income	$60M	$117M	-48.8%

Revenue Segments

Royalty

$134M97%

Research Fees

$5M3%

License

$86,0000%